Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF).
The company has reached a significant milestone in its Phase 2b clinical trial of avicursen (ATL-1102), a treatment for Duchenne muscular dystrophy. All 48 participants completed their week-25 visits, marking a key point in the trial focused on non-ambulant boys with advanced disease progression, a subgroup representing approximately half of the Duchenne population.
Data validation and statistical analysis are underway, with the six-month topline results expected to be released during the week of December 16. This readout will be the first to assess avicursen’s activity in Duchenne patients, guiding the company’s path toward potential registration and commercialisation. Additional results from the study are anticipated in mid-2025 and then the second half of 2025, including 16-month data.
Duchenne muscular dystrophy is a rare genetic condition causing progressive muscle degeneration, predominantly affecting males with a life expectancy of 22 …